ARZERRA Plus Chlorambucil Dosing—Two Infusion Visits in Cycle 1, Then One per Month Thereafter, in the First-Line Treatment of CLL1

ARZERRA Dosing Schedule in the Clinical Trial of Patients With Previously Untreated CLL1,2

  • Treatment should be continued for a minimum of three cycles, until best response,* or a maximum of 12 cycles (every 28 days)

Chlorambucil dosing schedule in the pivotal trial1

  • 10 mg/m2 each day orally for the first 7 days of each 28-day cycle

Patients in the Pivotal Trial Completed a Median of Six Cycles2

*Best response is a clinical response that did not improve with three additional cycles of treatment.

Find out how ARZERRA is dosed when used in combination with bendamustine.

References: 1. Arzerra® (ofatumumab) summary of product characteristics. West Sussex, UK; Novartis Europharm Limited; 2016. 2. Hillmen P, Robak T, Janssens A, et al, for the COMPLEMENT 1 Study Investigators. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873-1883.